Augmented CD3(+)CD8(+) and CD3(+)CD56(-) cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor.

[1]  Qi Zhang,et al.  Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. , 2015, World journal of hepatology.

[2]  J. Hong,et al.  Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells , 2015, Immune network.

[3]  Fang-ping Chen,et al.  Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia , 2014, Oncology letters.

[4]  C. Coch,et al.  Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC) , 2015, Journal of Cancer Research and Clinical Oncology.

[5]  Jun-Xia Cao,et al.  Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer , 2014, PloS one.

[6]  Min Wu,et al.  Cytokine-induced killer cells in the treatment of patients with renal cell carcinoma: a pooled meta-analysis. , 2014, Immunotherapy.

[7]  R. Bast,et al.  Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies , 2014, Clinical Cancer Research.

[8]  Y. Zeng,et al.  Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[9]  I. Schmidt-Wolf,et al.  Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal Tumors , 2014, Journal of immunology research.

[10]  C. Haymaker,et al.  PD-1 and BTLA and CD8+ T-cell “exhaustion” in cancer , 2012, Oncoimmunology.

[11]  S. Rosenberg,et al.  Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement , 2011, Journal of immunotherapy.

[12]  L. Moretta,et al.  Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. , 2011, Blood.

[13]  I. Schmidt-Wolf,et al.  Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? , 2011, Leukemia research.

[14]  Yijun Wang,et al.  Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function , 2011, Journal of immunotherapy.

[15]  X. Pan,et al.  Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. , 2010, Tissue antigens.

[16]  C. June,et al.  4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. , 2010, Clinical immunology.

[17]  L. H. Ng,et al.  Characterization of the recognition and functional heterogeneity exhibited by cytokine‐induced killer cell subsets against acute myeloid leukaemia target cell , 2009, Immunology.

[18]  Ying Han,et al.  Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. , 2009, Cytotherapy.

[19]  C. Usal,et al.  Myeloid-Derived Suppressor Cells Accumulate in Kidney Allograft Tolerance and Specifically Suppress Effector T Cell Expansion1 , 2008, The Journal of Immunology.

[20]  Hui Li,et al.  CD4+T cells in CIKs (CD4+ CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. , 2008, Cancer biotherapy & radiopharmaceuticals.

[21]  C. June,et al.  4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.

[22]  S. Forman,et al.  Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. , 2007, Experimental hematology.

[23]  D. Neuberg,et al.  Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell , 2007, Clinical Cancer Research.

[24]  T. Watts,et al.  IL-15-Dependent Induction of 4-1BB Promotes Antigen-Independent CD8 Memory T Cell Survival1 , 2006, The Journal of Immunology.

[25]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[26]  F. Finkelman,et al.  Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion , 2004, Cancer Research.

[27]  Julian A. Kim,et al.  Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells , 2004, Journal of Translational Medicine.

[28]  C. Ziske,et al.  Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer , 2004, Genetic vaccines and therapy.

[29]  Sujung Park,et al.  4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11 , 2002, The Journal of Immunology.

[30]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[31]  WangFS,et al.  Antitumor activities of human autologous cytokine—induced killer（CIK）cells against hepatocellular carcinoma cells in vitro and in vivo , 2002 .

[32]  T. Sauerbruch,et al.  Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. , 2001, Haematologica.

[33]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[34]  D. Taub,et al.  Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand , 1999 .

[35]  C. Takahashi,et al.  Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. , 1999, Journal of immunology.

[36]  D. Taub,et al.  Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. , 1999, Blood.

[37]  I. Herr,et al.  Induction of apoptosis by IFNγ in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit , 1999, Cell Death and Differentiation.

[38]  B. Kwon,et al.  Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. , 1997, Journal of immunology.

[39]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[40]  R. Negrin,et al.  A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. , 1994, Journal of immunology.

[41]  N. Copeland,et al.  Molecular cloning of a ligand for the inducible T cell gene 4‐1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor , 1993, European journal of immunology.

[42]  K. Pollok,et al.  Inducible T cell antigen 4-1BB. Analysis of expression and function. , 1993, Journal of immunology.

[43]  I. Weissman,et al.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.